Reporter, Medtech Insight
Graduating in 2020 with a Master’s degree in biomedical engineering from University College London, Barnaby is passionate about all things medtech. In his first role as a journalist, Barnaby will focus on R&D and commercial stories in medtech, and writing about emerging technologies such as digital health, artificial intelligence, machine learning, deep-brain implants, and nanoscale applications of medtech. Alongside this, Barnaby is looking forward to taking deeper dives into start-ups, device market analysis, and company financial data, to create informed, useful, and engaging content.
Barnaby lives in in rural Wiltshire, UK and is a keen reader, cyclist, and hobbyist jeweler.
Latest From Barnaby Pickering
The company expects the major commercial collaboration and geographical roll-out will lead to increased adoption of Agendia’s breast cancer diagnostics.
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022. Here are some highlights from the in vitro diagnostics companies that presented on the first two days of the meeting.
Medtech Insight spoke to Rutger Zietsma, Manus Neurodynamica’ CEO, to learn about the next commercial steps for the company's Neuromotor Pen for differential diagnosis of neuromotor impairment.
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
As Omicron further destabilizes the medtech space, potentially mirroring the spring of 2020, some executives shared with Medtech Insight their views on what will hopefully be a bumper year for the sector.
Medtech Insight spoke to the CEOs Blackrock Neurotech, and Pixium Vision, to find out how their devices can restore lost neurological function, and how devices that interface with the brain may shape the future of medicine.